IN2012DN01292A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01292A
IN2012DN01292A IN1292DEN2012A IN2012DN01292A IN 2012DN01292 A IN2012DN01292 A IN 2012DN01292A IN 1292DEN2012 A IN1292DEN2012 A IN 1292DEN2012A IN 2012DN01292 A IN2012DN01292 A IN 2012DN01292A
Authority
IN
India
Prior art keywords
therapy
preparing
processes
compound
formula
Prior art date
Application number
Inventor
Simon Craig Andrew
Zarah Ismail Salima
Maxwell Lawrence Ronnie
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of IN2012DN01292A publication Critical patent/IN2012DN01292A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

The invention relates to the compound of formula (I) in a crystalline anhydrate form, pharmaceutical formulations containing them, their use in therapy and processes for preparing the same.
IN1292DEN2012 2009-08-27 2010-08-25 IN2012DN01292A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23743509P 2009-08-27 2009-08-27
PCT/EP2010/062420 WO2011023733A1 (en) 2009-08-27 2010-08-25 Anhydrate forms of a pyridine derivative

Publications (1)

Publication Number Publication Date
IN2012DN01292A true IN2012DN01292A (en) 2015-06-05

Family

ID=42790943

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1292DEN2012 IN2012DN01292A (en) 2009-08-27 2010-08-25

Country Status (18)

Country Link
US (1) US8796269B2 (en)
EP (1) EP2470545B1 (en)
JP (3) JP2013503134A (en)
KR (1) KR20120056258A (en)
CN (1) CN102639536B (en)
AU (1) AU2010288502B2 (en)
BR (1) BR112012003435A2 (en)
CA (1) CA2772168C (en)
DK (1) DK2470545T3 (en)
EA (1) EA021411B1 (en)
ES (1) ES2440938T3 (en)
IL (1) IL217922A (en)
IN (1) IN2012DN01292A (en)
MX (1) MX2012002369A (en)
PL (1) PL2470545T3 (en)
SG (1) SG178231A1 (en)
WO (1) WO2011023733A1 (en)
ZA (1) ZA201200812B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011023733A1 (en) * 2009-08-27 2011-03-03 Glaxosmithkline Llc Anhydrate forms of a pyridine derivative
EP3160469B1 (en) * 2014-06-25 2021-04-28 Emory University Methods of managing conditioned fear with neurokinin receptor antagonists
PL3297631T3 (en) 2015-05-18 2020-03-31 Nerre Therapeutics Limited Nk-1/nk-3 receptor antagonist for the treatment of hot flushes
ES2901616T3 (en) * 2016-12-15 2022-03-23 Glaxosmithkline Ip Dev Ltd NRF2 compounds
JOP20200227A1 (en) 2018-03-14 2020-09-13 Kandy Therapeutics Ltd Novel pharmaceutical formulation comprising dual nk-1/nk-3 receptor antagonists
WO2021030335A1 (en) * 2019-08-12 2021-02-18 Millendo Therapeutics, Inc. A stereoisomerically pure nk-3 receptor antagonist and crystalline forms thereof
CN114728906A (en) 2019-11-15 2022-07-08 康堤医疗有限公司 Novel chemical method for preparing key intermediate 6-chloro-4- (4-fluoro-2-methylphenyl) pyridine-3-amine of NT-814

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60014216T2 (en) * 1999-02-24 2006-03-02 F. Hoffmann-La Roche Ag 4-phenylpyridine derivatives and their use as NK-1 receptor antagonists
GB0203022D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
BRPI0406702A (en) * 2003-01-31 2005-12-20 Hoffmann La Roche 2- (3,5-Bis-trifluoromethyl-phenyl) -n- [6- (1,1-dioxo-1-yl] -4,6-thiomorpholin-4-yl) -4- (4-fluoro-2) crystalline modification -methyl-phenyl) -pyridin-3-yl] -n-methyl-isobutyramide
NZ544244A (en) * 2003-07-03 2008-10-31 Hoffmann La Roche Dual NK1/NK3 antagonists for treating schizophrenia
CA2621564C (en) * 2005-09-09 2014-06-03 Smithkline Beecham Corporation Pyridine derivatives and their use in the treatment of psychotic disorders
KR20100101051A (en) * 2007-12-11 2010-09-16 씨아이피엘에이 엘티디. Crystalline polymorphic forms of zopiclone, processes for their preparation and their pharmaceutical compositions
GB0814340D0 (en) * 2008-08-05 2008-09-10 Smithkline Beecham Corp Anhydrous crystol form fo a pyridine derivative
WO2011023733A1 (en) * 2009-08-27 2011-03-03 Glaxosmithkline Llc Anhydrate forms of a pyridine derivative
JP6342662B2 (en) * 2014-01-29 2018-06-13 京セラ株式会社 Drill and method of manufacturing cut product using the same

Also Published As

Publication number Publication date
AU2010288502A1 (en) 2012-02-23
JP2016000739A (en) 2016-01-07
US20120157450A1 (en) 2012-06-21
CA2772168A1 (en) 2011-03-03
AU2010288502B2 (en) 2013-12-12
SG178231A1 (en) 2012-03-29
IL217922A (en) 2016-06-30
DK2470545T3 (en) 2014-01-13
KR20120056258A (en) 2012-06-01
JP2013503134A (en) 2013-01-31
EA021411B1 (en) 2015-06-30
BR112012003435A2 (en) 2016-02-23
ZA201200812B (en) 2013-03-27
CN102639536A (en) 2012-08-15
IL217922A0 (en) 2012-03-29
US8796269B2 (en) 2014-08-05
JP6404186B2 (en) 2018-10-10
EP2470545B1 (en) 2013-10-09
CN102639536B (en) 2015-03-18
EP2470545A1 (en) 2012-07-04
PL2470545T3 (en) 2014-03-31
CA2772168C (en) 2019-01-08
JP2017193564A (en) 2017-10-26
MX2012002369A (en) 2012-03-29
ES2440938T3 (en) 2014-01-31
WO2011023733A1 (en) 2011-03-03
EA201270302A1 (en) 2012-07-30

Similar Documents

Publication Publication Date Title
MX2011011661A (en) Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750.
MX2011008864A (en) Sulfonylated tetrahydroazolopyrazines and their use as medicinal products.
MY149731A (en) Compounds
NZ608116A (en) Triazine-oxadiazoles
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
UA109010C2 (en) Morpholino pyrividines and their use in therapy
MX2012013274A (en) Novel pyrimidine derivatives.
MX2010002461A (en) (carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament.
IN2014CN04530A (en)
MX2010002419A (en) (cyclopropyl-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament.
IN2012DN03182A (en)
MY187718A (en) Pharmaceutical formulations
MX2013010898A (en) Novel pyrimidine derivatives.
IN2012DN02139A (en)
MX2010002210A (en) Catecholamine derivatives and prodrugs thereof.
IN2015DN01119A (en)
IN2012DN01292A (en)
JO2682B1 (en) 7-ALkynyl-1,8-Naphthyridone Derivatives, Preparation Thereof And Therapeutic Use Thereof
MX2011011776A (en) Triptolide prodrugs.
UA110128C2 (en) Normal;heading 1;heading 2;heading 3;INDOLECARBOXAMIDES AND BENZIMIDAZOLECARBOXAMIDES AS INSECTICIDES AND ACARICIDES
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
MY160625A (en) Process for preparing pan-cdk inhibitors of the formula(i), and intermediates in the preparation
MX2012007253A (en) Tricyclic derivatives and their pharmaceutical use and compositions.
MX2011008126A (en) Substituted indole compounds as bradykinin receptor 1 modulators.
MY150428A (en) Tricyclic n-heteroaryl-carboxamide derivatives, preparation thereof and therapeutic use of same